The Board of Directors of Sopharma AD (the “Company”) announces that it took a decision to sell 8976 ordinary registered shares with voting rights, representing 51% of the capital of ZAO "Rostbalkanpharm", city of Azov, Rostov region, Russian Federation, divided into 17,600 common shares of emission with state registration № 1-01-58454-P.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from April 12 2012 up to and including April 18 2012 the Company bought 1000 own shares representing 0.000757% of the share capital of the Company, to the total value of BGN 2642.00 on the Bulgarian Stock Exchange. The average price per share was 2.64 BGN.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 19 April 2012 up to and including 24 April 2012 the Company bought 200 own shares representing 0.00015% of the share capital of the Company, to the total value of 521 BGN on the Bulgarian Stock Exchange. The average price per share was 2.61 BGN.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
We would like to notify that on 18 May 2012 (Friday) Sopharma AD will conduct a regular Annual Meeting with Investors, which will take place in the Conference center of Sopharma Business Towers. We kindly request that all interested parties notify us not later than May 11, 2012 by e-mail ir@sopharma.bg or by telephone +3592 8134 319 in order to receive their registration forms. Places is limited.
We would like to notify that for the month of April, 2012 Sopharma AD realized increase of sales revenues of 15% compared with the same month of the previous year, including 6% decrease of domestic sales and 23% increase of export sales.
During the first four months of this year, Sopharma AD realized increase of sales revenues of 1%, including 15 % decrease of domestic sales and 8% increase of export sales compared with the same quarter of 2011.
The Board of Directors of Sopharma AD (the “Company”) notifies that it took the decision to establish the "Sopharma Ukraine OOD" company with headquarters in Kiev, Ukraine and with share capital of 1,000,000 / one million / UAH. The aim of the company is to optimize the trading business in Ukraine.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 3 May 2012 up to and including 9 May 2012 the Company bought 700 own shares representing 0.00053% of the share capital of the Company, to the total value of BGN 1776.6 on the Bulgarian Stock Exchange. The average price per share was BGN 2.54.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 10 May 2012 up to and including 16 May 2012 the Company bought 3097 own shares representing 0.0023% of the share capital of the Company, to the total value of BGN 7515.54 on the Bulgarian Stock Exchange. The average price per share was BGN 2.427.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 17 May 2012 up to and including 23 May 2012 the Company bought 40800 own shares representing 0.031% of the share capital of the Company, to the total value of BGN 94444 on the Bulgarian Stock Exchange. The average price per share was BGN 2.314.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
We would like to notify that for the month of May, 2012 Sopharma AD realized decrease of sales revenues of 2% compared with the same month of the previous year, including same level of export sales and 7% decrease of domestic sales.
During the first five months of this year Sopharma AD realized increase of sales revenues of 1%, including 13% decrease of domestic sales and 6% increase of export sales compared with the same period of 2011.
